2018 ASCO/CAP Her2 Testing Guidelines in Breast Cancer. Impact of the Updated Guidelines on Breast Carcinomas Originally Classified as Her2 Equivocal - A Retrospective Analysis

被引：0
|
作者：
Alzeer, Ali [1 ]
Zeck, Jay [1 ]
Laureano, Julio [1 ]
Sidawy, Mary [1 ]
机构：
[1] MedStar Georgetown Univ Hosp, Washington, DC USA
来源：
LABORATORY INVESTIGATION | 2019年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
108
引用
收藏
页数：2
相关论文
共 50 条
  • [41] HER2 testing in breast cancers: comparison of assays and interpretation using ASCO/CAP 2013 and 2018 guidelines
    Lauren E. McLemore
    Constance T. Albarracin
    Stephen K. Gruschkus
    Roland L. Bassett
    Yun Wu
    Sagar Dhamne
    Isaiah Yim
    Kevin Lin
    Isabelle Bedrosian
    Nour Sneige
    Hui Chen
    Breast Cancer Research and Treatment, 2021, 187 : 95 - 104
  • [42] The updated ASCO/CAP guidelines for HER2 testing create more uncertainty for clinicians
    Chen, J.
    Klein, P.
    Shao, T.
    CANCER RESEARCH, 2016, 76
  • [43] Pathological and Clinical Features Associated with Invasive Breast Cancer ISH Group 3 Classified According to the 2018 CAP/ASCO HER2 Guidelines: A Retrospective Analysis
    Mohamed, Nada
    Asirvatham, Jaya
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 165 - 166
  • [44] The Impact of 2018 ASCO-CAP HER2 Testing Guidelines on Breast Cancer HER2 Results. An audit of 2136 consecutive cases evaluated by Immunohistochemistry and In Situ Hybridization
    Farshid, Gelareh
    Dhatrak, Deepak
    Gilhotra, Amardeep
    Koszyca, Barbara
    Nolan, James
    LABORATORY INVESTIGATION, 2019, 99
  • [45] The Impact of 2018 ASCO-CAP HER2 Testing Guidelines on Breast Cancer HER2 Results. An audit of 2136 consecutive cases evaluated by Immunohistochemistry and In Situ Hybridization
    Farshid, Gelareh
    Dhatrak, Deepak
    Gilhotra, Amardeep
    Koszyca, Barbara
    Nolan, James
    MODERN PATHOLOGY, 2019, 32
  • [46] Pathological and Clinical Features Associated with Invasive Breast Cancer ISH Group 3 Classified According to the 2018 CAP/ASCO HER2 Guidelines: A Retrospective Analysis
    Mohamed, Nada
    Asirvatham, Jaya
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 165 - 166
  • [47] The impact of 2018 ASCO-CAP HER2 testing guidelines on breast cancer HER2 results. An audit of 2132 consecutive cases evaluated by immunohistochemistry and in situ hybridization
    Farshid, Gelareh
    Dhatrak, Deepak
    Gilhotra, Amardeep
    Koszyca, Barbara
    Nolan, James
    MODERN PATHOLOGY, 2020, 33 (09) : 1783 - 1790
  • [48] Retrospective analysis of 2200 HER2 cases evaluated according to the 2013 ASCO/CAP guidelines and its correlation with the updated 2018 guideline and its impact in HER2 status
    Bermudez Cameo, R. I.
    Almanzar Comas, H. P.
    Eizaguirre Zarza, B.
    Bakali Badesa, S.
    Franco, J. I.
    Viso Soriano, M. J.
    Sobrino Prados, A.
    Arellano Alvarez, A.
    Estrada Mallarino, N.
    Del Agua, C.
    Gimeno Esteras, E.
    Sanz Salvador, V.
    Malo Nieves, V.
    VIRCHOWS ARCHIV, 2019, 475 : S66 - S66
  • [49] Adherence to ASCO/CAP HER2 Testing Guidelines: Equivocal Rates and Impact on Management within a Single Institution
    Portier, B. P.
    Downs-Kelly, E.
    Lanigan, C.
    Cotta, C.
    Patil, D.
    Procop, G.
    Cook, J. R.
    Moore, H.
    Budd, G. T.
    Tubbs, R. R.
    MODERN PATHOLOGY, 2011, 24 : 436A - 436A
  • [50] Adherence to ASCO/CAP HER2 Testing Guidelines: Equivocal Rates and Impact on Management within a Single Institution
    Portier, B. P.
    Downs-Kelly, E.
    Lanigan, C.
    Cotta, C.
    Patil, D.
    Procop, G.
    Cook, J. R.
    Moore, H.
    Budd, G. T.
    Tubbs, R. R.
    LABORATORY INVESTIGATION, 2011, 91 : 436A - 436A
12345